Pembrolizumab for Liver Cancer

Not currently recruiting at 321 trial locations

Overseen By Toll Free Number

Age: 18+

Sex: Any

Trial Phase: Phase 3

Sponsor: Merck Sharp & Dohme Corp.

Must not be taking: Antineoplastics, Immunotherapy, Steroids, others

Disqualifiers: Active infection, HIV, Autoimmune, others

Stay on Your Current Meds You can continue your current medications while participating

Pivotal Trial (Near Approval) This treatment is in the last trial phase before FDA approval

Prior Safety Data This treatment has passed at least one previous human trial

Breakthrough Therapy This drug has been fast-tracked for approval by the FDA given its high promise

Compensation: Varies

Number of Visits: 17

Duration: Approximately 1 year

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests pembrolizumab, an experimental drug, to determine if it can help people with liver cancer (specifically hepatocellular carcinoma) live longer without cancer recurrence after surgery or local treatment. Participants will receive either pembrolizumab or a placebo for comparison. It is designed for individuals whose liver cancer has been completely removed or treated and who currently show no signs of the disease. Eligible participants should have controlled hepatitis B and no other active cancers or infections. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking treatment advancements.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications. However, you cannot take certain therapies like systemic chemotherapy, immunotherapy not specified in the protocol, or systemic glucocorticoids. It's best to discuss your current medications with the trial team.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research has shown that pembrolizumab has been studied for safety in treating liver cancer. In one study, almost all patients (98.7%) who received pembrolizumab experienced some side effects. However, these side effects were mostly manageable, and the treatment was generally well-tolerated. Another study assessed the safety of pembrolizumab in liver cancer patients by examining treatment-related side effects. Serious side effects occurred, but they were not common.

These findings suggest that while side effects can occur, pembrolizumab is usually tolerated by patients. Notably, pembrolizumab is already approved for other types of cancer, which provides some confidence in its safety. When considering joining a trial, discussing possible side effects with the study team or a doctor is important. ^{1 2 3 4 5}

Why do researchers think this study treatment might be promising for liver cancer?

Pembrolizumab is unique because it leverages the body's immune system to fight liver cancer by targeting and blocking the PD-1 pathway, which helps cancer cells evade immune detection. This mechanism is different from traditional treatments like chemotherapy, which directly kill cancer cells but can also harm healthy cells. Researchers are excited about pembrolizumab because it offers a more targeted approach, potentially leading to fewer side effects and improved outcomes for patients with liver cancer.

What evidence suggests that pembrolizumab might be an effective treatment for liver cancer?

In this trial, participants will receive either pembrolizumab, also known as Keytruda, or a placebo. Research has shown that pembrolizumab may help treat liver cancer. Studies have found that pembrolizumab can extend the lives of patients with advanced liver cancer. In one study, patients who received pembrolizumab lived for an average of 14.6 months, compared to 13.0 months for those who received a placebo. Another study demonstrated that pembrolizumab can effectively stop the cancer from growing or spreading for a significant time. These findings suggest that pembrolizumab could be a helpful additional treatment for liver cancer after surgery or other local treatments. ^{1 3 6 7 8}

Who Is on the Research Team?

Medical Director

Principal Investigator

Merck Sharp & Dohme LLC

Are You a Good Fit for This Trial?

This trial is for people who've had liver cancer (HCC) treated with surgery or local ablation and show no signs of the disease on scans. They must be in good physical condition, not pregnant or breastfeeding, using effective contraception if applicable, have a stable liver function score (Child-Pugh class A), controlled hepatitis B, and no other recent cancers or certain infections like HIV.

Inclusion Criteria

I have recovered from any side effects of my cancer surgery or local treatment.

My scans show no cancer signs 4 weeks after surgery or local treatment.

Has alpha fetoprotein (AFP) concentration lower than 400 ng/mL within 28 days prior to Cycle 1, Day 1

Exclusion Criteria

I have or had lung inflammation that needed steroids.

I have active tuberculosis.

I have had bleeding from varices in my esophagus or stomach in the last 6 months.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive intravenous pembrolizumab or placebo on Day 1 of each 21-day cycle for up to 17 cycles

Approximately 1 year

17 visits (in-person)

Follow-up

Participants are monitored for recurrence-free survival and overall survival

Up to 8 years

What Are the Treatments Tested in This Trial?

Interventions

• Pembrolizumab
• Placebo

Trial Overview The study tests whether pembrolizumab, an immunotherapy drug, is better than a placebo at preventing cancer from coming back after treatment (recurrence-free survival) and improving overall survival rates in patients whose liver cancer was removed or destroyed.

How Is the Trial Designed?

Group I: Pembrolizumab Experimental Treatment 1 Intervention

Participants receive intravenous (IV) pembrolizumab at 200 mg on Day 1 of each 21-day cycle for up to 17 cycles.

Group II: Placebo Placebo Group 1 Intervention

Participants receive IV placebo on Day 1 of each 21-day cycle for up to 17 cycles.

Who Is Running the Clinical Trial?

Merck Sharp & Dohme Corp.

Lead Sponsor

Trials

2,287

Recruited

4,582,000+

Chirfi Guindo

Merck Sharp & Dohme Corp.

Chief Medical Officer

Engineering degree from Ecole Centrale de Paris, MBA from New York University Stern School of Business

Robert M. Davis

Merck Sharp & Dohme Corp.

Chief Executive Officer since 2021

J.D. from Northwestern University Pritzker School of Law, MBA from Northwestern University Kellogg Graduate School of Management, Bachelor's in Finance from Miami University

Merck Sharp & Dohme LLC

Lead Sponsor

Trials

4,096

Recruited

5,232,000+

Chirfi Guindo

Merck Sharp & Dohme LLC

Chief Marketing Officer since 2022

Degree in Engineering from Ecole Centrale de Paris, MBA from New York University Stern School of Business

Robert M. Davis

Merck Sharp & Dohme LLC

Chief Executive Officer since 2021

JD from Northwestern University Pritzker School of Law, MBA from Northwestern University Kellogg Graduate School of Management, Bachelor's in Finance from Miami University

Published Research Related to This Trial

Pembrolizumab (KEYTRUDA) was approved by the FDA for treating advanced melanoma, showing an overall response rate of 24% in a trial of 89 patients, with 86% of responses lasting at least 6 months.

While there are potential immune-mediated side effects, the benefits of prolonged tumor response durations were deemed to outweigh these risks, marking an improvement over existing treatments.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

FDA Approval Summary: Accelerated Approval of Pembrolizumab for Second-Line Treatment of Metastatic Melanoma. Chuk, MK., Chang, JT., Theoret, MR., et al.[2021]

In a study of 41 pancreas cancer patients treated with pembrolizumab, the median overall survival was 7.2 months, which is considered favorable compared to the benchmark of over 4 months.

Patients with specific genetic markers (dMMR, MSI-H, TMB-H, or Lynch syndrome) had a significantly lower risk of death, indicating that these biomarkers may help identify patients who could benefit more from pembrolizumab treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Pembrolizumab near the end of life in patients with metastatic pancreatic cancer: a multi-site consecutive series to examine survival and patient treatment burden. Storandt, MH., Tran, N., Martin, N., et al.[2023]

In a phase 3 trial involving 1019 patients with resected high-risk stage III melanoma, pembrolizumab significantly improved distant metastasis-free survival at 3.5 years, with 65.3% of patients in the pembrolizumab group remaining free of distant metastasis compared to 49.4% in the placebo group (HR 0.60).

The study also showed that pembrolizumab led to longer recurrence-free survival, with 59.8% of patients in the pembrolizumab group remaining free of recurrence compared to 41.4% in the placebo group, reinforcing its efficacy as an adjuvant therapy for this patient population.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Eggermont, AMM., Blank, CU., Mandalà, M., et al.[2021]

Pembrolizumab (Keytruda) was approved by the FDA for treating metastatic non-small cell lung cancer (mNSCLC) in patients with tumors expressing PD-L1, showing significant improvements in overall survival (OS) and progression-free survival (PFS) in two major clinical trials with thousands of participants.

In the KEYNOTE-024 trial, pembrolizumab demonstrated a 40% reduction in the risk of death compared to chemotherapy, while in the KEYNOTE-010 trial, it also showed a significant survival advantage over chemotherapy in patients who had previously progressed on treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond. Pai-Scherf, L., Blumenthal, GM., Li, H., et al.[2022]

In a phase II trial involving 15 patients with resectable non-small cell lung cancer (NSCLC), neoadjuvant treatment with pembrolizumab showed a major pathologic response in 27% of patients, indicating promising antitumor activity before surgery.

The treatment was found to be feasible and safe, with only 33% of patients experiencing moderate adverse events, and no postoperative mortality, suggesting that pembrolizumab does not compromise surgical outcomes.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: First clinical experience. Eichhorn, F., Klotz, LV., Kriegsmann, M., et al.[2022]

In a phase III study involving 413 patients with advanced hepatocellular carcinoma (HCC) previously treated with sorafenib, pembrolizumab showed a median overall survival of 13.9 months compared to 10.6 months for placebo, indicating its potential effectiveness as a treatment option.

While pembrolizumab demonstrated improved overall survival and progression-free survival compared to placebo, the study noted a higher incidence of grade 3 or higher adverse events, suggesting a need to weigh the benefits against the risks when considering this therapy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. Finn, RS., Ryoo, BY., Merle, P., et al.[2020]

In a phase 3 study involving 794 patients with unresectable hepatocellular carcinoma, the combination of pembrolizumab and lenvatinib showed a median overall survival of 21.2 months, compared to 19.0 months for lenvatinib plus placebo, indicating a potential benefit in survival.

Despite the observed improvement in overall survival, the combination therapy did not meet the predefined significance thresholds for overall survival and progression-free survival, suggesting that it may not warrant a change in current treatment practices.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Llovet, JM., Kudo, M., Merle, P., et al.[2023]

In a study of 29 patients with advanced hepatocellular carcinoma (HCC) treated with pembrolizumab, the overall response rate was 32%, with one complete response and eight partial responses, indicating that pembrolizumab can be an effective treatment option for this patient group.

The treatment was generally well-tolerated, with reversible grade 3/4 adverse events, and high baseline levels of TGF-β in plasma were identified as a potential predictive biomarker for poor treatment outcomes.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma. Feun, LG., Li, YY., Wu, C., et al.[2020]

Pembrolizumab (Keytruda) effectively blocks the PD-1 pathway, enhancing T-cell activity against tumors, which supports its role in promoting tumor regression and immune rejection.

Preclinical studies in cynomolgus monkeys showed that pembrolizumab has a favorable safety profile with no significant toxicological findings, aligning with its demonstrated safety and efficacy in human clinical trials.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Biophysical and Immunological Characterization and In Vivo Pharmacokinetics and Toxicology in Nonhuman Primates of the Anti-PD-1 Antibody Pembrolizumab. Hutchins, B., Starling, GC., McCoy, MA., et al.[2021]

In a study of 120 patients with advanced hepatocellular carcinoma (HCC), both nivolumab and pembrolizumab showed comparable efficacy, with response rates of 8.0% for pembrolizumab and 7.4% for nivolumab, and similar median progression-free survival (PFS) of 2.7 months and 2.9 months, respectively.

The median overall survival (OS) was longer for nivolumab at 10.8 months compared to 8.1 months for pembrolizumab, but this difference was not statistically significant, indicating that both treatments are similarly effective in real-world settings.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma. Chen, YH., Tsai, CH., Chen, YY., et al.[2023]

Pembrolizumab, an immune checkpoint inhibitor, can cause pneumonitis in 1%-5% of patients, and this case report highlights an atypical presentation of this side effect in a patient with metastatic squamous cell carcinoma.

The patient was successfully treated with steroid therapy after ruling out other potential causes, leading to complete resolution of the pneumonitis, emphasizing the importance of recognizing and managing atypical cases of checkpoint inhibitor-pneumonitis.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Recurrent and atypical immune checkpoint inhibitor-induced pneumonitis. Jeon, WJ., Nguyen, J., Castillo, DR., et al.[2023]

In a phase Ib trial involving 26 patients with advanced PD-L1-positive ovarian cancer, pembrolizumab demonstrated a confirmed objective response rate of 11.5%, indicating some level of antitumor activity, with 1 complete response and 2 partial responses observed.

The treatment was generally well-tolerated, with 73.1% of patients experiencing treatment-related adverse events, but no deaths or treatment discontinuations due to these events, suggesting that pembrolizumab has a manageable safety profile.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028. Varga, A., Piha-Paul, S., Ott, PA., et al.[2019]

Pembrolizumab, a PD-1 inhibitor, has demonstrated clinical effectiveness in treating various solid tumors, particularly in patients with PD-L1-positive non-small-cell lung cancer and unresectable/metastatic melanoma.

Early-phase trials and ongoing studies are focused on further confirming the clinical benefits of pembrolizumab in thoracic malignancies, highlighting its potential as a significant treatment option in cancer therapy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Pembrolizumab for the treatment of thoracic malignancies: current landscape and future directions. Karim, S., Leighl, N.[2017]

Citations

1. merck.com merck.com/news/merck-and-eisai-provide-update-on-phase-3-leap-012-trial-in-unresectable-non-metastatic-hepatocellular-carcinoma/

Merck and Eisai Provide Update on Phase 3 LEAP-012 ... As reported previously, KEYTRUDA plus LENVIMA in combination with TACE met the study's other primary endpoint of progression-free survival (PFS) ...

2. merck.com merck.com/news/mercks-keytruda-pembrolizumab-significantly-improved-overall-survival-os-versus-placebo-in-certain-patients-with-advanced-hepatocellular-carcinoma-hcc-previously-treated-with-sora/

Merck's KEYTRUDA® (pembrolizumab) Significantly ... For patients treated with KEYTRUDA plus BSC, median OS was 14.6 months (95% CI, 12.6-18.0) compared to 13.0 months (95% CI, 10.5-15.1) for ...

3. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC9784157/

Data from the Open-Label, Phase II KEYNOTE-224 Trial - PMC Our results show that pembrolizumab monotherapy provided durable antitumor activity and promising OS in patients with advanced HCC who had not received prior ...

4. ascopubs.org ascopubs.org/doi/10.1200/GO-25-00128

Effectiveness and Safety of Immunotherapy for ... The median treatment duration was 4.9 months, and the median overall survival (OS) was 14.7 months (95% CI, 11.6 to 24.5), with 12- and 24-month ...

5. clinicaltrials.gov clinicaltrials.gov/study/NCT02702401

NCT02702401 | Study of Pembrolizumab (MK-3475) vs. ... This is a study of pembrolizumab (MK-3475) in participants with previously systemically treated advanced hepatocellular carcinoma (HCC).

6. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC11145164/

Safety and Preliminary Efficacy of Pembrolizumab Following ... Safety and preliminary efficacy of pembrolizumab following transarterial chemoembolization for hepatocellular carcinoma: The PETAL Phase Ib study.

7. cancernetwork.com cancernetwork.com/view/pembrolizumab-combo-does-not-significantly-improve-os-in-unresectable-hcc

Pembrolizumab Combo Does Not Significantly Improve OS ... Safety data from the first interim analysis revealed that 98.7% of patients treated with the investigational regimen vs 84.6% in the TACE-only ...

8. clinicaltrials.gov clinicaltrials.gov/study/NCT02658019

Pembrolizumab (Keytruda) in Advanced Hepatocellular ... The safety of Pembrolizumab in HCC patients as measured by the incidence of treatment-related adverse events, including serious adverse events (SAEs), in study ...